CTOs on the Move

X4 Pharmaceuticals

www.x4pharma.com

 
X4 Pharmaceuticals (Nasdaq: XFOR) is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company`s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4`s most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.x4pharma.com
  • 955 Massachusetts Avenue 4th Floor
    Cambridge, MA USA 02139
  • Phone: 857.529.8300

Executives

Name Title Contact Details
Patrick Breznak
Director - IT Operations, Infastructure, Security Profile

Funding

X4 Pharmaceuticals raised $37.5M on 08/28/2015
X4 Pharmaceuticals raised $27M on 11/16/2017
X4 Pharmaceuticals raised $55M on 03/19/2021

Similar Companies

MnPharm

MNPHARM SBC is a manufacturer of recombinant regenerative proteins using a proprietary method called molecular farming. We supply these proteins to researchers working on therapeutic development. Our plant based expression method only takes 6 to 8 days. We offer faster production and lower cost resulting in rapid therapeutic development.

Cambridge Major Laboratories

Cambridge Major Laboratories is a leading global chemistry outsourcing partner to the pharmaceutical and biotechnology industries

MENARINI Group

The Menarini Group is an Italian pharmaceutical company.

Curie Therapeutics

Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective. Curie`s radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emitting radionuclide payloads. Curie`s mission is to revolutionize the use of radiomedicines in cancer.

MCR American Pharmaceuticals

MCR American Pharmaceuticals, Inc. was established in 1991. Our product line consists of Allfen, Ambifed, Ambi, Maxifed, Maxinate, Maxiphen, Promacet and Time-Hist QD. Our sales representatives are located throughout the United States. We will continue